Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05028829 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Atorvastatin v. Placebo on HCC Risk
A Phase 2 study of Cirrhosis and Liver Fibroses, sponsored by Raymond Chung.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 2
- Study locations
NCT05028829 is a Phase 2 study of Cirrhosis and Liver Fibroses that is actively recruiting participants, run by Raymond Chung. The registered enrollment target is 60 participants, below the 90,408-participant average among 53 other Cirrhosis trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT05028829, a Phase 2 study of Cirrhosis and Liver Fibroses, is actively recruiting participants, sponsored by Raymond Chung.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 2
- Study locations
Study Summary
Prospective randomized, multi-center, double blind placebo-controlled trial to assess the chemopreventive impact of atorvastatin (20 mg oral) vs placebo in up to 60 adults with advanced fibrosis at high risk of developing HCC.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Atorvastatin 20mg
Study Locations (2)
Massachusetts
- Massachusetts General Hospital - Boston
Texas
- University of Texas Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2023-05-10 |
| Est. Completion | 2031-03-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05028829
The ClinicalTrials.gov registry entry for NCT05028829 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 90,408-participant average among 53 other Cirrhosis trials with a reported enrollment target (100% lower). The listed sponsor is Raymond Chung, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cirrhosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05028829 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, Texas.
Frequently Asked Questions
What is clinical trial NCT05028829 about?
NCT05028829 is a clinical study titled "Safety and Efficacy of Atorvastatin v. Placebo on HCC Risk". Prospective randomized, multi-center, double blind placebo-controlled trial to assess the chemopreventive impact of atorvastatin (20 mg oral) vs placebo in up to 60 adults with advanced fibrosis at high risk of developing HCC.
What is the current status of trial NCT05028829?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2023-05-10. Estimated completion is 2031-03-01.
What conditions does trial NCT05028829 study?
This clinical trial studies the following conditions: Cirrhosis, Liver Fibroses.
What interventions are being tested in trial NCT05028829?
The interventions under investigation include: Placebo (DRUG), Atorvastatin 20mg (DRUG).
Who is sponsoring clinical trial NCT05028829?
This trial is sponsored by Raymond Chung, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05028829 being conducted?
This trial has 2 study locations across Massachusetts, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cirrhosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Droxidopa to Increase Mean Arterial Pressure in Decompensated Cirrhosis Patients With Acute Kidney Injury
RECRUITING · Phase 2
-
A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer
RECRUITING · Phase 2
-
Hepatic Encephalopathy and Albumin Lasting Cognitive Improvement
RECRUITING · Phase 2
-
Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
RECRUITING · Phase 2
-
Statin and Beta Blocker Use in Patients With Decompensated Cirrhosis
RECRUITING · Phase 2
-
Empagliflozin in Patients With Cirrhosis and Ascites
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.